It is intriguing to envision that blocking the PD-L1/PD-1 interaction between cancer cells and TAMs through anti-PD-L1/PD-1 therapy may turn the TAMs against their host cancer cells and thus achieve therapeutic efficacy, particularly in those immunologically cold tumors. Here, PDCD1 is linked to cancer.